共 16 条
[1]
Diamantopoulos A.(2012)Validity of cost and utility results? [letter] Pharmacoeconomics 30 977-93
[2]
Sawyer L.(2012)Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model Pharmacoeconomics 30 575-7
[3]
Ogale S.(1989)Castigating QALYs J Med Ethics 15 143-23
[4]
Nguyen C.M.(2004)A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study J Formos Med Assoc 103 618-81
[5]
Bounthavong M.(2004)Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675-9
[6]
Mendes M.A.S.(1999)A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253-undefined
[7]
Rawles J.(undefined)undefined undefined undefined undefined-undefined
[8]
Lan J.L.(undefined)undefined undefined undefined undefined-undefined
[9]
Chou S.J.(undefined)undefined undefined undefined undefined-undefined
[10]
Chen D.Y.(undefined)undefined undefined undefined undefined-undefined